Pacira BioSciences, Inc. Stock

Equities

PCRX

US6951271005

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-15 pm EDT 5-day change 1st Jan Change
26.53 USD -1.12% Intraday chart for Pacira BioSciences, Inc. -6.85% -21.37%
Sales 2024 * 694M Sales 2025 * 764M Capitalization 1.25B
Net income 2024 * 60M Net income 2025 * 91M EV / Sales 2024 * 1.92 x
Net Debt 2024 * 83.94M Net cash position 2025 * 119M EV / Sales 2025 * 1.48 x
P/E ratio 2024 *
21.9 x
P/E ratio 2025 *
13.8 x
Employees 712
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.78%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Pacira BioSciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM
Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation MT
Pacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis DJ
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy Designation for the Treatment of Osteoarthritis of the Knee CI
Pacira Biosciences Insider Sold Shares Worth $3,656,226, According to a Recent SEC Filing MT
RBC Cuts Price Target on Pacira BioSciences to $45 From $53, Keeps Outperform Rating MT
Pacira BioSciences' Shares Rise After Company Posts Higher Q4 Non-GAAP Net Income, Revenue MT
Transcript : Pacira BioSciences, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Pacira BioSciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024 CI
Pacira BioSciences, Inc. Provides Earnings Guidance for the Year 2024 CI
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q4 Revenue $181.2M, vs. Street Est of $180.9M MT
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q4 EPS $0.89, vs. Street Est of $0.85 MT
North American Morning Briefing : Fed's Preferred -2- DJ
Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy CI
More news
1 day-1.94%
1 week-4.72%
Current month-8.18%
1 month-8.30%
3 months-16.74%
6 months-7.93%
Current year-20.48%
More quotes
1 week
26.61
Extreme 26.61
28.84
1 month
26.61
Extreme 26.61
30.39
Current year
26.61
Extreme 26.61
35.95
1 year
25.93
Extreme 25.93
48.60
3 years
25.93
Extreme 25.93
82.16
5 years
25.93
Extreme 25.93
82.16
10 years
25.93
Extreme 25.93
121.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 Jan. 01
Director of Finance/CFO 63 11-10-31
Chief Tech/Sci/R&D Officer 49 21-06-30
Members of the board TitleAgeSince
Director/Board Member 76 08-05-31
Chairman 64 11-06-01
Director/Board Member 64 06-11-30
More insiders
Date Price Change Volume
24-04-15 26.53 -1.12% 604,436
24-04-12 26.83 -1.94% 471,623
24-04-11 27.36 -1.69% 323,567
24-04-10 27.83 -2.42% 444,858
24-04-09 28.52 +0.14% 363,924

Delayed Quote Nasdaq, April 12, 2024 at 04:00 pm EDT

More quotes
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
26.83 USD
Average target price
45.73 USD
Spread / Average Target
+70.43%
Consensus